Global Anticancer Biologics Supply, Demand and Key Producers, 2026-2032
The global Anticancer Biologics market size is expected to reach $ 217860 million by 2032, rising at a market growth of 9.0% CAGR during the forecast period (2026-2032).
Anticancer Biologics are a class of biologic medicines that use antibodies, proteins, cells, viruses, or other biologically derived substances as their primary active components to treat cancer through mechanisms such as specifically recognizing tumor-associated targets, modulating immune responses, directly eliminating tumor cells, blocking tumor growth signaling pathways, or altering the tumor microenvironment. Anticancer Biologics mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies, and are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and other malignant tumors.
Anticancer Biologics represent an important segment of modern cancer therapy and mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies. Compared with conventional chemotherapy, Anticancer Biologics generally offer greater target specificity, more clearly defined mechanisms of action, and the ability to activate or modulate the immune system. They are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and various other malignancies.
From an industry value-chain perspective, the upstream segment mainly includes cell lines, culture media, single-use bioreactors, chromatography media, filtration materials, pharmaceutical excipients, as well as key materials such as antibodies, payloads, and linkers. The midstream segment covers drug discovery, cell-line development, process development, drug-substance manufacturing, formulation, aseptic filling, quality control, and clinical development. Downstream demand mainly comes from general hospitals, oncology specialty hospitals, hematology treatment centers, and other specialized medical institutions. Antibody-based products are generally manufactured at scale through mammalian cell culture and bioreactor systems, with individual production lines ranging from several thousand liters to tens of thousands of liters in capacity, while cell therapies and cancer vaccines typically rely on smaller-batch, more flexible, and in some cases patient-specific manufacturing models.
The Anticancer Biologics industry is characterized by long development cycles, high technological barriers, stringent regulatory requirements, and substantial capital investment. Manufacturing costs are influenced by cell-culture productivity, protein expression levels, purification yields, raw material costs, production scale, and capacity utilization. Mature antibody products can generally achieve relatively attractive gross margins once large-scale production is established, while cell therapies, complex bispecific antibodies, and certain antibody-drug conjugates tend to carry higher manufacturing costs because of their more complicated production processes, smaller batch sizes, and stricter quality-control requirements. Advances in continuous manufacturing, single-use bioreactors, high-expression cell lines, and automated quality-control technologies are steadily improving manufacturing efficiency across the industry.
The competitive landscape is shaped by both large multinational pharmaceutical companies and biotechnology companies with differentiated technology platforms. Large pharmaceutical companies generally benefit from stronger capabilities in clinical development, global regulatory registration, commercialization, and large-scale manufacturing, while emerging biotechnology companies compete through innovative approaches such as bispecific antibodies, antibody-drug conjugates, cell therapies, and novel immuno-oncology targets. Chinese companies have developed rapidly in areas including PD-1/PD-L1 antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies, and are increasingly expanding into global markets through licensing agreements, co-development partnerships, and international clinical trials.
Looking forward, the Anticancer Biologics industry is expected to evolve from conventional single-target monoclonal antibodies toward bispecific and multispecific antibodies, next-generation antibody-drug conjugates, cell therapies, and combination treatments involving multiple mechanisms of action. Biomarker-based patient selection, precision treatment, subcutaneous formulations, long-acting formulations, and more efficient manufacturing processes are also expected to become increasingly important sources of clinical and commercial differentiation. As more biologic therapies move from later-line treatment into first-line, neoadjuvant, and adjuvant settings, Anticancer Biologics are expected to play an increasingly important role in the global cancer treatment landscape.
This report is a detailed and comprehensive analysis of the world market for Anticancer Biologics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anticancer Biologics that contribute to its increasing demand across many markets.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Anticancer Biologics market
2. What is the demand of the global Anticancer Biologics market?
3. What is the year over year growth of the global Anticancer Biologics market?
4. What is the total value of the global Anticancer Biologics market?
5. Who are the Major Players in the global Anticancer Biologics market?
6. What are the growth factors driving the market demand?
Anticancer Biologics are a class of biologic medicines that use antibodies, proteins, cells, viruses, or other biologically derived substances as their primary active components to treat cancer through mechanisms such as specifically recognizing tumor-associated targets, modulating immune responses, directly eliminating tumor cells, blocking tumor growth signaling pathways, or altering the tumor microenvironment. Anticancer Biologics mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies, and are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and other malignant tumors.
Anticancer Biologics represent an important segment of modern cancer therapy and mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies. Compared with conventional chemotherapy, Anticancer Biologics generally offer greater target specificity, more clearly defined mechanisms of action, and the ability to activate or modulate the immune system. They are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and various other malignancies.
From an industry value-chain perspective, the upstream segment mainly includes cell lines, culture media, single-use bioreactors, chromatography media, filtration materials, pharmaceutical excipients, as well as key materials such as antibodies, payloads, and linkers. The midstream segment covers drug discovery, cell-line development, process development, drug-substance manufacturing, formulation, aseptic filling, quality control, and clinical development. Downstream demand mainly comes from general hospitals, oncology specialty hospitals, hematology treatment centers, and other specialized medical institutions. Antibody-based products are generally manufactured at scale through mammalian cell culture and bioreactor systems, with individual production lines ranging from several thousand liters to tens of thousands of liters in capacity, while cell therapies and cancer vaccines typically rely on smaller-batch, more flexible, and in some cases patient-specific manufacturing models.
The Anticancer Biologics industry is characterized by long development cycles, high technological barriers, stringent regulatory requirements, and substantial capital investment. Manufacturing costs are influenced by cell-culture productivity, protein expression levels, purification yields, raw material costs, production scale, and capacity utilization. Mature antibody products can generally achieve relatively attractive gross margins once large-scale production is established, while cell therapies, complex bispecific antibodies, and certain antibody-drug conjugates tend to carry higher manufacturing costs because of their more complicated production processes, smaller batch sizes, and stricter quality-control requirements. Advances in continuous manufacturing, single-use bioreactors, high-expression cell lines, and automated quality-control technologies are steadily improving manufacturing efficiency across the industry.
The competitive landscape is shaped by both large multinational pharmaceutical companies and biotechnology companies with differentiated technology platforms. Large pharmaceutical companies generally benefit from stronger capabilities in clinical development, global regulatory registration, commercialization, and large-scale manufacturing, while emerging biotechnology companies compete through innovative approaches such as bispecific antibodies, antibody-drug conjugates, cell therapies, and novel immuno-oncology targets. Chinese companies have developed rapidly in areas including PD-1/PD-L1 antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies, and are increasingly expanding into global markets through licensing agreements, co-development partnerships, and international clinical trials.
Looking forward, the Anticancer Biologics industry is expected to evolve from conventional single-target monoclonal antibodies toward bispecific and multispecific antibodies, next-generation antibody-drug conjugates, cell therapies, and combination treatments involving multiple mechanisms of action. Biomarker-based patient selection, precision treatment, subcutaneous formulations, long-acting formulations, and more efficient manufacturing processes are also expected to become increasingly important sources of clinical and commercial differentiation. As more biologic therapies move from later-line treatment into first-line, neoadjuvant, and adjuvant settings, Anticancer Biologics are expected to play an increasingly important role in the global cancer treatment landscape.
Report Scope
This report studies the global Anticancer Biologics demand, key companies, and key regions.This report is a detailed and comprehensive analysis of the world market for Anticancer Biologics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anticancer Biologics that contribute to its increasing demand across many markets.
Highlights and key features of the study
- Global Anticancer Biologics total market, 2021-2032, (USD Million)
- Global Anticancer Biologics total market by region & country, CAGR, 2021-2032, (USD Million)
- U.S. VS China: Anticancer Biologics total market, key domestic companies, and share, (USD Million)
- Global Anticancer Biologics revenue by player, revenue and market share 2021-2026, (USD Million)
- Global Anticancer Biologics total market by Type, CAGR, 2021-2032, (USD Million)
- Global Anticancer Biologics total market by Application, CAGR, 2021-2032, (USD Million)
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Anticancer Biologics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.Global Anticancer Biologics Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
Market Segmentation
Global Anticancer Biologics Market, Segmentation by Type:
- Antibody Therapies
- Antibody-Drug Conjugates (ADCs)
- Cell Therapies
- Cancer Vaccines and Oncolytic Viruses
- Others
Global Anticancer Biologics Market, Segmentation by Target:
- Immune Checkpoint Targets
- Solid Tumor-Associated Targets
- Hematologic Tumor Targets
- Angiogenesis-Related Targets
- Others
Global Anticancer Biologics Market, Segmentation by Route of Administration:
- Intravenous Administration
- Subcutaneous Administration
- Cell Infusion
- Intratumoral Administration
- Others
Global Anticancer Biologics Market, Segmentation by Application:
- Lung Cancer
- Breast Cancer
- Hematologic Cancers
- Gastrointestinal Cancers
- Others
Companies Profiled:
- AbbVie Inc.
- Johnson & Johnson
- Novartis AG
- Gilead Sciences, Inc.
- Roche Holding AG
- Bristol-Myers Squibb Company
- Amgen Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Merck KGaA
- Eli Lilly and Company
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.
- GSK plc
- Regeneron Pharmaceuticals, Inc.
- Innovent Biologics, Inc.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- Akeso, Inc.
- Shanghai Henlius Biotech, Inc.
- RemeGen Co., Ltd.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Sino Biopharmaceutical Limited
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
Key Questions Answered
1. How big is the global Anticancer Biologics market?2. What is the demand of the global Anticancer Biologics market?
3. What is the year over year growth of the global Anticancer Biologics market?
4. What is the total value of the global Anticancer Biologics market?
5. Who are the Major Players in the global Anticancer Biologics market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Anticancer Biologics Introduction
1.2 World Anticancer Biologics Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Anticancer Biologics Total Market by Region (by Headquarter Location)
1.3.1 World Anticancer Biologics Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Anticancer Biologics Revenue (2021-2032)
1.3.3 China Based Company Anticancer Biologics Revenue (2021-2032)
1.3.4 Europe Based Company Anticancer Biologics Revenue (2021-2032)
1.3.5 Japan Based Company Anticancer Biologics Revenue (2021-2032)
1.3.6 South Korea Based Company Anticancer Biologics Revenue (2021-2032)
1.3.7 ASEAN Based Company Anticancer Biologics Revenue (2021-2032)
1.3.8 India Based Company Anticancer Biologics Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anticancer Biologics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Anticancer Biologics Consumption Value (2021-2032)
2.2 World Anticancer Biologics Consumption Value by Region
2.2.1 World Anticancer Biologics Consumption Value by Region (2021-2026)
2.2.2 World Anticancer Biologics Consumption Value Forecast by Region (2027-2032)
2.3 United States Anticancer Biologics Consumption Value (2021-2032)
2.4 China Anticancer Biologics Consumption Value (2021-2032)
2.5 Europe Anticancer Biologics Consumption Value (2021-2032)
2.6 Japan Anticancer Biologics Consumption Value (2021-2032)
2.7 South Korea Anticancer Biologics Consumption Value (2021-2032)
2.8 ASEAN Anticancer Biologics Consumption Value (2021-2032)
2.9 India Anticancer Biologics Consumption Value (2021-2032)
3 WORLD ANTICANCER BIOLOGICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Anticancer Biologics Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Anticancer Biologics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Anticancer Biologics in 2025
3.2.3 Global Concentration Ratios (CR8) for Anticancer Biologics in 2025
3.3 Anticancer Biologics Company Evaluation Quadrant
3.4 Anticancer Biologics Market: Overall Company Footprint Analysis
3.4.1 Anticancer Biologics Market: Region Footprint
3.4.2 Anticancer Biologics Market: Company Product Type Footprint
3.4.3 Anticancer Biologics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Anticancer Biologics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Anticancer Biologics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Anticancer Biologics Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Anticancer Biologics Consumption Value Comparison
4.2.1 United States VS China: Anticancer Biologics Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Anticancer Biologics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Anticancer Biologics Companies and Market Share, 2021-2026
4.3.1 United States Based Anticancer Biologics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Anticancer Biologics Revenue, (2021-2026)
4.4 China Based Companies Anticancer Biologics Revenue and Market Share, 2021-2026
4.4.1 China Based Anticancer Biologics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Anticancer Biologics Revenue, (2021-2026)
4.5 Rest of World Based Anticancer Biologics Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Anticancer Biologics Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Anticancer Biologics Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Anticancer Biologics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Antibody Therapies
5.2.2 Antibody-Drug Conjugates (ADCs)
5.2.3 Cell Therapies
5.2.4 Cancer Vaccines and Oncolytic Viruses
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Anticancer Biologics Market Size by Type (2021-2026)
5.3.2 World Anticancer Biologics Market Size by Type (2027-2032)
5.3.3 World Anticancer Biologics Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY TARGET
6.1 World Anticancer Biologics Market Size Overview by Target: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Target
6.2.1 Immune Checkpoint Targets
6.2.2 Solid Tumor-Associated Targets
6.2.3 Hematologic Tumor Targets
6.2.4 Angiogenesis-Related Targets
6.2.5 Others
6.3 Market Segment by Target
6.3.1 World Anticancer Biologics Market Size by Target (2021-2026)
6.3.2 World Anticancer Biologics Market Size by Target (2027-2032)
6.3.3 World Anticancer Biologics Market Size Market Share by Target (2027-2032)
7 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1 World Anticancer Biologics Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Route of Administration
7.2.1 Intravenous Administration
7.2.2 Subcutaneous Administration
7.2.3 Cell Infusion
7.2.4 Intratumoral Administration
7.2.5 Others
7.3 Market Segment by Route of Administration
7.3.1 World Anticancer Biologics Market Size by Route of Administration (2021-2026)
7.3.2 World Anticancer Biologics Market Size by Route of Administration (2027-2032)
7.3.3 World Anticancer Biologics Market Size Market Share by Route of Administration (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Anticancer Biologics Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Lung Cancer
8.2.2 Breast Cancer
8.2.3 Hematologic Cancers
8.2.4 Gastrointestinal Cancers
8.2.5 Others
8.3 Market Segment by Application
8.3.1 World Anticancer Biologics Market Size by Application (2021-2026)
8.3.2 World Anticancer Biologics Market Size by Application (2027-2032)
8.3.3 World Anticancer Biologics Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 AbbVie Inc. Details
9.1.2 AbbVie Inc. Major Business
9.1.3 AbbVie Inc. Anticancer Biologics Product and Services
9.1.4 AbbVie Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 AbbVie Inc. Recent Developments/Updates
9.1.6 AbbVie Inc. Competitive Strengths & Weaknesses
9.2 Johnson & Johnson
9.2.1 Johnson & Johnson Details
9.2.2 Johnson & Johnson Major Business
9.2.3 Johnson & Johnson Anticancer Biologics Product and Services
9.2.4 Johnson & Johnson Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Johnson & Johnson Recent Developments/Updates
9.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.3 Novartis AG
9.3.1 Novartis AG Details
9.3.2 Novartis AG Major Business
9.3.3 Novartis AG Anticancer Biologics Product and Services
9.3.4 Novartis AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Novartis AG Recent Developments/Updates
9.3.6 Novartis AG Competitive Strengths & Weaknesses
9.4 Gilead Sciences, Inc.
9.4.1 Gilead Sciences, Inc. Details
9.4.2 Gilead Sciences, Inc. Major Business
9.4.3 Gilead Sciences, Inc. Anticancer Biologics Product and Services
9.4.4 Gilead Sciences, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Gilead Sciences, Inc. Recent Developments/Updates
9.4.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
9.5 Roche Holding AG
9.5.1 Roche Holding AG Details
9.5.2 Roche Holding AG Major Business
9.5.3 Roche Holding AG Anticancer Biologics Product and Services
9.5.4 Roche Holding AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Roche Holding AG Recent Developments/Updates
9.5.6 Roche Holding AG Competitive Strengths & Weaknesses
9.6 Bristol-Myers Squibb Company
9.6.1 Bristol-Myers Squibb Company Details
9.6.2 Bristol-Myers Squibb Company Major Business
9.6.3 Bristol-Myers Squibb Company Anticancer Biologics Product and Services
9.6.4 Bristol-Myers Squibb Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Bristol-Myers Squibb Company Recent Developments/Updates
9.6.6 Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
9.7 Amgen Inc.
9.7.1 Amgen Inc. Details
9.7.2 Amgen Inc. Major Business
9.7.3 Amgen Inc. Anticancer Biologics Product and Services
9.7.4 Amgen Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Amgen Inc. Recent Developments/Updates
9.7.6 Amgen Inc. Competitive Strengths & Weaknesses
9.8 AstraZeneca plc
9.8.1 AstraZeneca plc Details
9.8.2 AstraZeneca plc Major Business
9.8.3 AstraZeneca plc Anticancer Biologics Product and Services
9.8.4 AstraZeneca plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 AstraZeneca plc Recent Developments/Updates
9.8.6 AstraZeneca plc Competitive Strengths & Weaknesses
9.9 Merck & Co., Inc.
9.9.1 Merck & Co., Inc. Details
9.9.2 Merck & Co., Inc. Major Business
9.9.3 Merck & Co., Inc. Anticancer Biologics Product and Services
9.9.4 Merck & Co., Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Merck & Co., Inc. Recent Developments/Updates
9.9.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
9.10 Takeda Pharmaceutical Company Limited
9.10.1 Takeda Pharmaceutical Company Limited Details
9.10.2 Takeda Pharmaceutical Company Limited Major Business
9.10.3 Takeda Pharmaceutical Company Limited Anticancer Biologics Product and Services
9.10.4 Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
9.10.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
9.11 Merck KGaA
9.11.1 Merck KGaA Details
9.11.2 Merck KGaA Major Business
9.11.3 Merck KGaA Anticancer Biologics Product and Services
9.11.4 Merck KGaA Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Merck KGaA Recent Developments/Updates
9.11.6 Merck KGaA Competitive Strengths & Weaknesses
9.12 Eli Lilly and Company
9.12.1 Eli Lilly and Company Details
9.12.2 Eli Lilly and Company Major Business
9.12.3 Eli Lilly and Company Anticancer Biologics Product and Services
9.12.4 Eli Lilly and Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Eli Lilly and Company Recent Developments/Updates
9.12.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.13 Ono Pharmaceutical Co., Ltd.
9.13.1 Ono Pharmaceutical Co., Ltd. Details
9.13.2 Ono Pharmaceutical Co., Ltd. Major Business
9.13.3 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product and Services
9.13.4 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Ono Pharmaceutical Co., Ltd. Recent Developments/Updates
9.13.6 Ono Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.14 Pfizer Inc.
9.14.1 Pfizer Inc. Details
9.14.2 Pfizer Inc. Major Business
9.14.3 Pfizer Inc. Anticancer Biologics Product and Services
9.14.4 Pfizer Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Pfizer Inc. Recent Developments/Updates
9.14.6 Pfizer Inc. Competitive Strengths & Weaknesses
9.15 GSK plc
9.15.1 GSK plc Details
9.15.2 GSK plc Major Business
9.15.3 GSK plc Anticancer Biologics Product and Services
9.15.4 GSK plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 GSK plc Recent Developments/Updates
9.15.6 GSK plc Competitive Strengths & Weaknesses
9.16 Regeneron Pharmaceuticals, Inc.
9.16.1 Regeneron Pharmaceuticals, Inc. Details
9.16.2 Regeneron Pharmaceuticals, Inc. Major Business
9.16.3 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product and Services
9.16.4 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
9.16.6 Regeneron Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
9.17 Innovent Biologics, Inc.
9.17.1 Innovent Biologics, Inc. Details
9.17.2 Innovent Biologics, Inc. Major Business
9.17.3 Innovent Biologics, Inc. Anticancer Biologics Product and Services
9.17.4 Innovent Biologics, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Innovent Biologics, Inc. Recent Developments/Updates
9.17.6 Innovent Biologics, Inc. Competitive Strengths & Weaknesses
9.18 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
9.18.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details
9.18.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
9.18.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product and Services
9.18.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
9.18.6 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
9.19 Shanghai Junshi Biosciences Co., Ltd.
9.19.1 Shanghai Junshi Biosciences Co., Ltd. Details
9.19.2 Shanghai Junshi Biosciences Co., Ltd. Major Business
9.19.3 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product and Services
9.19.4 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Shanghai Junshi Biosciences Co., Ltd. Recent Developments/Updates
9.19.6 Shanghai Junshi Biosciences Co., Ltd. Competitive Strengths & Weaknesses
9.20 Akeso, Inc.
9.20.1 Akeso, Inc. Details
9.20.2 Akeso, Inc. Major Business
9.20.3 Akeso, Inc. Anticancer Biologics Product and Services
9.20.4 Akeso, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Akeso, Inc. Recent Developments/Updates
9.20.6 Akeso, Inc. Competitive Strengths & Weaknesses
9.21 Shanghai Henlius Biotech, Inc.
9.21.1 Shanghai Henlius Biotech, Inc. Details
9.21.2 Shanghai Henlius Biotech, Inc. Major Business
9.21.3 Shanghai Henlius Biotech, Inc. Anticancer Biologics Product and Services
9.21.4 Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Shanghai Henlius Biotech, Inc. Recent Developments/Updates
9.21.6 Shanghai Henlius Biotech, Inc. Competitive Strengths & Weaknesses
9.22 RemeGen Co., Ltd.
9.22.1 RemeGen Co., Ltd. Details
9.22.2 RemeGen Co., Ltd. Major Business
9.22.3 RemeGen Co., Ltd. Anticancer Biologics Product and Services
9.22.4 RemeGen Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 RemeGen Co., Ltd. Recent Developments/Updates
9.22.6 RemeGen Co., Ltd. Competitive Strengths & Weaknesses
9.23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
9.23.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details
9.23.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
9.23.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product and Services
9.23.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments/Updates
9.23.6 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.24 Sino Biopharmaceutical Limited
9.24.1 Sino Biopharmaceutical Limited Details
9.24.2 Sino Biopharmaceutical Limited Major Business
9.24.3 Sino Biopharmaceutical Limited Anticancer Biologics Product and Services
9.24.4 Sino Biopharmaceutical Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Sino Biopharmaceutical Limited Recent Developments/Updates
9.24.6 Sino Biopharmaceutical Limited Competitive Strengths & Weaknesses
9.25 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
9.25.1 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Details
9.25.2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Major Business
9.25.3 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product and Services
9.25.4 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Recent Developments/Updates
9.25.6 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Competitive Strengths & Weaknesses
9.26 Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
9.26.1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Details
9.26.2 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Major Business
9.26.3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product and Services
9.26.4 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recent Developments/Updates
9.26.6 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Anticancer Biologics Industry Chain
10.2 Anticancer Biologics Upstream Analysis
10.3 Anticancer Biologics Midstream Analysis
10.4 Anticancer Biologics Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Anticancer Biologics Introduction
1.2 World Anticancer Biologics Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Anticancer Biologics Total Market by Region (by Headquarter Location)
1.3.1 World Anticancer Biologics Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Anticancer Biologics Revenue (2021-2032)
1.3.3 China Based Company Anticancer Biologics Revenue (2021-2032)
1.3.4 Europe Based Company Anticancer Biologics Revenue (2021-2032)
1.3.5 Japan Based Company Anticancer Biologics Revenue (2021-2032)
1.3.6 South Korea Based Company Anticancer Biologics Revenue (2021-2032)
1.3.7 ASEAN Based Company Anticancer Biologics Revenue (2021-2032)
1.3.8 India Based Company Anticancer Biologics Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anticancer Biologics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Anticancer Biologics Consumption Value (2021-2032)
2.2 World Anticancer Biologics Consumption Value by Region
2.2.1 World Anticancer Biologics Consumption Value by Region (2021-2026)
2.2.2 World Anticancer Biologics Consumption Value Forecast by Region (2027-2032)
2.3 United States Anticancer Biologics Consumption Value (2021-2032)
2.4 China Anticancer Biologics Consumption Value (2021-2032)
2.5 Europe Anticancer Biologics Consumption Value (2021-2032)
2.6 Japan Anticancer Biologics Consumption Value (2021-2032)
2.7 South Korea Anticancer Biologics Consumption Value (2021-2032)
2.8 ASEAN Anticancer Biologics Consumption Value (2021-2032)
2.9 India Anticancer Biologics Consumption Value (2021-2032)
3 WORLD ANTICANCER BIOLOGICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Anticancer Biologics Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Anticancer Biologics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Anticancer Biologics in 2025
3.2.3 Global Concentration Ratios (CR8) for Anticancer Biologics in 2025
3.3 Anticancer Biologics Company Evaluation Quadrant
3.4 Anticancer Biologics Market: Overall Company Footprint Analysis
3.4.1 Anticancer Biologics Market: Region Footprint
3.4.2 Anticancer Biologics Market: Company Product Type Footprint
3.4.3 Anticancer Biologics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Anticancer Biologics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Anticancer Biologics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Anticancer Biologics Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Anticancer Biologics Consumption Value Comparison
4.2.1 United States VS China: Anticancer Biologics Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Anticancer Biologics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Anticancer Biologics Companies and Market Share, 2021-2026
4.3.1 United States Based Anticancer Biologics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Anticancer Biologics Revenue, (2021-2026)
4.4 China Based Companies Anticancer Biologics Revenue and Market Share, 2021-2026
4.4.1 China Based Anticancer Biologics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Anticancer Biologics Revenue, (2021-2026)
4.5 Rest of World Based Anticancer Biologics Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Anticancer Biologics Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Anticancer Biologics Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Anticancer Biologics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Antibody Therapies
5.2.2 Antibody-Drug Conjugates (ADCs)
5.2.3 Cell Therapies
5.2.4 Cancer Vaccines and Oncolytic Viruses
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Anticancer Biologics Market Size by Type (2021-2026)
5.3.2 World Anticancer Biologics Market Size by Type (2027-2032)
5.3.3 World Anticancer Biologics Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY TARGET
6.1 World Anticancer Biologics Market Size Overview by Target: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Target
6.2.1 Immune Checkpoint Targets
6.2.2 Solid Tumor-Associated Targets
6.2.3 Hematologic Tumor Targets
6.2.4 Angiogenesis-Related Targets
6.2.5 Others
6.3 Market Segment by Target
6.3.1 World Anticancer Biologics Market Size by Target (2021-2026)
6.3.2 World Anticancer Biologics Market Size by Target (2027-2032)
6.3.3 World Anticancer Biologics Market Size Market Share by Target (2027-2032)
7 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1 World Anticancer Biologics Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Route of Administration
7.2.1 Intravenous Administration
7.2.2 Subcutaneous Administration
7.2.3 Cell Infusion
7.2.4 Intratumoral Administration
7.2.5 Others
7.3 Market Segment by Route of Administration
7.3.1 World Anticancer Biologics Market Size by Route of Administration (2021-2026)
7.3.2 World Anticancer Biologics Market Size by Route of Administration (2027-2032)
7.3.3 World Anticancer Biologics Market Size Market Share by Route of Administration (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Anticancer Biologics Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Lung Cancer
8.2.2 Breast Cancer
8.2.3 Hematologic Cancers
8.2.4 Gastrointestinal Cancers
8.2.5 Others
8.3 Market Segment by Application
8.3.1 World Anticancer Biologics Market Size by Application (2021-2026)
8.3.2 World Anticancer Biologics Market Size by Application (2027-2032)
8.3.3 World Anticancer Biologics Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 AbbVie Inc. Details
9.1.2 AbbVie Inc. Major Business
9.1.3 AbbVie Inc. Anticancer Biologics Product and Services
9.1.4 AbbVie Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 AbbVie Inc. Recent Developments/Updates
9.1.6 AbbVie Inc. Competitive Strengths & Weaknesses
9.2 Johnson & Johnson
9.2.1 Johnson & Johnson Details
9.2.2 Johnson & Johnson Major Business
9.2.3 Johnson & Johnson Anticancer Biologics Product and Services
9.2.4 Johnson & Johnson Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Johnson & Johnson Recent Developments/Updates
9.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.3 Novartis AG
9.3.1 Novartis AG Details
9.3.2 Novartis AG Major Business
9.3.3 Novartis AG Anticancer Biologics Product and Services
9.3.4 Novartis AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Novartis AG Recent Developments/Updates
9.3.6 Novartis AG Competitive Strengths & Weaknesses
9.4 Gilead Sciences, Inc.
9.4.1 Gilead Sciences, Inc. Details
9.4.2 Gilead Sciences, Inc. Major Business
9.4.3 Gilead Sciences, Inc. Anticancer Biologics Product and Services
9.4.4 Gilead Sciences, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Gilead Sciences, Inc. Recent Developments/Updates
9.4.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
9.5 Roche Holding AG
9.5.1 Roche Holding AG Details
9.5.2 Roche Holding AG Major Business
9.5.3 Roche Holding AG Anticancer Biologics Product and Services
9.5.4 Roche Holding AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Roche Holding AG Recent Developments/Updates
9.5.6 Roche Holding AG Competitive Strengths & Weaknesses
9.6 Bristol-Myers Squibb Company
9.6.1 Bristol-Myers Squibb Company Details
9.6.2 Bristol-Myers Squibb Company Major Business
9.6.3 Bristol-Myers Squibb Company Anticancer Biologics Product and Services
9.6.4 Bristol-Myers Squibb Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Bristol-Myers Squibb Company Recent Developments/Updates
9.6.6 Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
9.7 Amgen Inc.
9.7.1 Amgen Inc. Details
9.7.2 Amgen Inc. Major Business
9.7.3 Amgen Inc. Anticancer Biologics Product and Services
9.7.4 Amgen Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Amgen Inc. Recent Developments/Updates
9.7.6 Amgen Inc. Competitive Strengths & Weaknesses
9.8 AstraZeneca plc
9.8.1 AstraZeneca plc Details
9.8.2 AstraZeneca plc Major Business
9.8.3 AstraZeneca plc Anticancer Biologics Product and Services
9.8.4 AstraZeneca plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 AstraZeneca plc Recent Developments/Updates
9.8.6 AstraZeneca plc Competitive Strengths & Weaknesses
9.9 Merck & Co., Inc.
9.9.1 Merck & Co., Inc. Details
9.9.2 Merck & Co., Inc. Major Business
9.9.3 Merck & Co., Inc. Anticancer Biologics Product and Services
9.9.4 Merck & Co., Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Merck & Co., Inc. Recent Developments/Updates
9.9.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
9.10 Takeda Pharmaceutical Company Limited
9.10.1 Takeda Pharmaceutical Company Limited Details
9.10.2 Takeda Pharmaceutical Company Limited Major Business
9.10.3 Takeda Pharmaceutical Company Limited Anticancer Biologics Product and Services
9.10.4 Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
9.10.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
9.11 Merck KGaA
9.11.1 Merck KGaA Details
9.11.2 Merck KGaA Major Business
9.11.3 Merck KGaA Anticancer Biologics Product and Services
9.11.4 Merck KGaA Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Merck KGaA Recent Developments/Updates
9.11.6 Merck KGaA Competitive Strengths & Weaknesses
9.12 Eli Lilly and Company
9.12.1 Eli Lilly and Company Details
9.12.2 Eli Lilly and Company Major Business
9.12.3 Eli Lilly and Company Anticancer Biologics Product and Services
9.12.4 Eli Lilly and Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Eli Lilly and Company Recent Developments/Updates
9.12.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.13 Ono Pharmaceutical Co., Ltd.
9.13.1 Ono Pharmaceutical Co., Ltd. Details
9.13.2 Ono Pharmaceutical Co., Ltd. Major Business
9.13.3 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product and Services
9.13.4 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Ono Pharmaceutical Co., Ltd. Recent Developments/Updates
9.13.6 Ono Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.14 Pfizer Inc.
9.14.1 Pfizer Inc. Details
9.14.2 Pfizer Inc. Major Business
9.14.3 Pfizer Inc. Anticancer Biologics Product and Services
9.14.4 Pfizer Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Pfizer Inc. Recent Developments/Updates
9.14.6 Pfizer Inc. Competitive Strengths & Weaknesses
9.15 GSK plc
9.15.1 GSK plc Details
9.15.2 GSK plc Major Business
9.15.3 GSK plc Anticancer Biologics Product and Services
9.15.4 GSK plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 GSK plc Recent Developments/Updates
9.15.6 GSK plc Competitive Strengths & Weaknesses
9.16 Regeneron Pharmaceuticals, Inc.
9.16.1 Regeneron Pharmaceuticals, Inc. Details
9.16.2 Regeneron Pharmaceuticals, Inc. Major Business
9.16.3 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product and Services
9.16.4 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
9.16.6 Regeneron Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
9.17 Innovent Biologics, Inc.
9.17.1 Innovent Biologics, Inc. Details
9.17.2 Innovent Biologics, Inc. Major Business
9.17.3 Innovent Biologics, Inc. Anticancer Biologics Product and Services
9.17.4 Innovent Biologics, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Innovent Biologics, Inc. Recent Developments/Updates
9.17.6 Innovent Biologics, Inc. Competitive Strengths & Weaknesses
9.18 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
9.18.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details
9.18.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
9.18.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product and Services
9.18.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
9.18.6 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
9.19 Shanghai Junshi Biosciences Co., Ltd.
9.19.1 Shanghai Junshi Biosciences Co., Ltd. Details
9.19.2 Shanghai Junshi Biosciences Co., Ltd. Major Business
9.19.3 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product and Services
9.19.4 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Shanghai Junshi Biosciences Co., Ltd. Recent Developments/Updates
9.19.6 Shanghai Junshi Biosciences Co., Ltd. Competitive Strengths & Weaknesses
9.20 Akeso, Inc.
9.20.1 Akeso, Inc. Details
9.20.2 Akeso, Inc. Major Business
9.20.3 Akeso, Inc. Anticancer Biologics Product and Services
9.20.4 Akeso, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Akeso, Inc. Recent Developments/Updates
9.20.6 Akeso, Inc. Competitive Strengths & Weaknesses
9.21 Shanghai Henlius Biotech, Inc.
9.21.1 Shanghai Henlius Biotech, Inc. Details
9.21.2 Shanghai Henlius Biotech, Inc. Major Business
9.21.3 Shanghai Henlius Biotech, Inc. Anticancer Biologics Product and Services
9.21.4 Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Shanghai Henlius Biotech, Inc. Recent Developments/Updates
9.21.6 Shanghai Henlius Biotech, Inc. Competitive Strengths & Weaknesses
9.22 RemeGen Co., Ltd.
9.22.1 RemeGen Co., Ltd. Details
9.22.2 RemeGen Co., Ltd. Major Business
9.22.3 RemeGen Co., Ltd. Anticancer Biologics Product and Services
9.22.4 RemeGen Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 RemeGen Co., Ltd. Recent Developments/Updates
9.22.6 RemeGen Co., Ltd. Competitive Strengths & Weaknesses
9.23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
9.23.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details
9.23.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
9.23.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product and Services
9.23.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments/Updates
9.23.6 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.24 Sino Biopharmaceutical Limited
9.24.1 Sino Biopharmaceutical Limited Details
9.24.2 Sino Biopharmaceutical Limited Major Business
9.24.3 Sino Biopharmaceutical Limited Anticancer Biologics Product and Services
9.24.4 Sino Biopharmaceutical Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Sino Biopharmaceutical Limited Recent Developments/Updates
9.24.6 Sino Biopharmaceutical Limited Competitive Strengths & Weaknesses
9.25 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
9.25.1 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Details
9.25.2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Major Business
9.25.3 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product and Services
9.25.4 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Recent Developments/Updates
9.25.6 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Competitive Strengths & Weaknesses
9.26 Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
9.26.1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Details
9.26.2 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Major Business
9.26.3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product and Services
9.26.4 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recent Developments/Updates
9.26.6 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Anticancer Biologics Industry Chain
10.2 Anticancer Biologics Upstream Analysis
10.3 Anticancer Biologics Midstream Analysis
10.4 Anticancer Biologics Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Anticancer Biologics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Anticancer Biologics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Anticancer Biologics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Anticancer Biologics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Anticancer Biologics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Anticancer Biologics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Anticancer Biologics Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Anticancer Biologics Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Anticancer Biologics Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Anticancer Biologics Players in 2025
Table 12. World Anticancer Biologics Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Anticancer Biologics Company Evaluation Quadrant
Table 14. Head Office of Key Anticancer Biologics Players
Table 15. Anticancer Biologics Market: Company Product Type Footprint
Table 16. Anticancer Biologics Market: Company Product Application Footprint
Table 17. Anticancer Biologics Mergers & Acquisitions Activity
Table 18. United States VS China Anticancer Biologics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Anticancer Biologics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Anticancer Biologics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Anticancer Biologics Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Anticancer Biologics Revenue Market Share (2021-2026)
Table 23. China Based Anticancer Biologics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Anticancer Biologics Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Anticancer Biologics Revenue Market Share (2021-2026)
Table 26. Rest of World Based Anticancer Biologics Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Anticancer Biologics Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Anticancer Biologics Revenue Market Share (2021-2026)
Table 29. World Anticancer Biologics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Anticancer Biologics Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Anticancer Biologics Market Size by Type (2027-2032) & (USD Million)
Table 32. World Anticancer Biologics Market Size by Target, (USD Million), 2021 & 2025 & 2032
Table 33. World Anticancer Biologics Market Size Value by Target (2021-2026) & (USD Million)
Table 34. World Anticancer Biologics Market Size by Target (2027-2032) & (USD Million)
Table 35. World Anticancer Biologics Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 36. World Anticancer Biologics Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 37. World Anticancer Biologics Market Size by Route of Administration (2027-2032) & (USD Million)
Table 38. World Anticancer Biologics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Anticancer Biologics Market Size by Application (2021-2026) & (USD Million)
Table 40. World Anticancer Biologics Market Size by Application (2027-2032) & (USD Million)
Table 41. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 42. AbbVie Inc. Major Business
Table 43. AbbVie Inc. Anticancer Biologics Product and Services
Table 44. AbbVie Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. AbbVie Inc. Recent Developments/Updates
Table 46. AbbVie Inc. Competitive Strengths & Weaknesses
Table 47. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 48. Johnson & Johnson Major Business
Table 49. Johnson & Johnson Anticancer Biologics Product and Services
Table 50. Johnson & Johnson Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Johnson & Johnson Recent Developments/Updates
Table 52. Johnson & Johnson Competitive Strengths & Weaknesses
Table 53. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 54. Novartis AG Major Business
Table 55. Novartis AG Anticancer Biologics Product and Services
Table 56. Novartis AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Novartis AG Recent Developments/Updates
Table 58. Novartis AG Competitive Strengths & Weaknesses
Table 59. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 60. Gilead Sciences, Inc. Major Business
Table 61. Gilead Sciences, Inc. Anticancer Biologics Product and Services
Table 62. Gilead Sciences, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Gilead Sciences, Inc. Recent Developments/Updates
Table 64. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 65. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 66. Roche Holding AG Major Business
Table 67. Roche Holding AG Anticancer Biologics Product and Services
Table 68. Roche Holding AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Roche Holding AG Recent Developments/Updates
Table 70. Roche Holding AG Competitive Strengths & Weaknesses
Table 71. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 72. Bristol-Myers Squibb Company Major Business
Table 73. Bristol-Myers Squibb Company Anticancer Biologics Product and Services
Table 74. Bristol-Myers Squibb Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Bristol-Myers Squibb Company Recent Developments/Updates
Table 76. Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
Table 77. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 78. Amgen Inc. Major Business
Table 79. Amgen Inc. Anticancer Biologics Product and Services
Table 80. Amgen Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Amgen Inc. Recent Developments/Updates
Table 82. Amgen Inc. Competitive Strengths & Weaknesses
Table 83. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 84. AstraZeneca plc Major Business
Table 85. AstraZeneca plc Anticancer Biologics Product and Services
Table 86. AstraZeneca plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. AstraZeneca plc Recent Developments/Updates
Table 88. AstraZeneca plc Competitive Strengths & Weaknesses
Table 89. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 90. Merck & Co., Inc. Major Business
Table 91. Merck & Co., Inc. Anticancer Biologics Product and Services
Table 92. Merck & Co., Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Merck & Co., Inc. Recent Developments/Updates
Table 94. Merck & Co., Inc. Competitive Strengths & Weaknesses
Table 95. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors
Table 96. Takeda Pharmaceutical Company Limited Major Business
Table 97. Takeda Pharmaceutical Company Limited Anticancer Biologics Product and Services
Table 98. Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 100. Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
Table 101. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 102. Merck KGaA Major Business
Table 103. Merck KGaA Anticancer Biologics Product and Services
Table 104. Merck KGaA Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Merck KGaA Recent Developments/Updates
Table 106. Merck KGaA Competitive Strengths & Weaknesses
Table 107. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 108. Eli Lilly and Company Major Business
Table 109. Eli Lilly and Company Anticancer Biologics Product and Services
Table 110. Eli Lilly and Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Eli Lilly and Company Recent Developments/Updates
Table 112. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 113. Ono Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 114. Ono Pharmaceutical Co., Ltd. Major Business
Table 115. Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product and Services
Table 116. Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Ono Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 118. Ono Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 119. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 120. Pfizer Inc. Major Business
Table 121. Pfizer Inc. Anticancer Biologics Product and Services
Table 122. Pfizer Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Pfizer Inc. Recent Developments/Updates
Table 124. Pfizer Inc. Competitive Strengths & Weaknesses
Table 125. GSK plc Basic Information, Manufacturing Base and Competitors
Table 126. GSK plc Major Business
Table 127. GSK plc Anticancer Biologics Product and Services
Table 128. GSK plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. GSK plc Recent Developments/Updates
Table 130. GSK plc Competitive Strengths & Weaknesses
Table 131. Regeneron Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 132. Regeneron Pharmaceuticals, Inc. Major Business
Table 133. Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product and Services
Table 134. Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 136. Regeneron Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 137. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors
Table 138. Innovent Biologics, Inc. Major Business
Table 139. Innovent Biologics, Inc. Anticancer Biologics Product and Services
Table 140. Innovent Biologics, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Innovent Biologics, Inc. Recent Developments/Updates
Table 142. Innovent Biologics, Inc. Competitive Strengths & Weaknesses
Table 143. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 144. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
Table 145. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product and Services
Table 146. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
Table 148. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
Table 149. Shanghai Junshi Biosciences Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 150. Shanghai Junshi Biosciences Co., Ltd. Major Business
Table 151. Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product and Services
Table 152. Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Shanghai Junshi Biosciences Co., Ltd. Recent Developments/Updates
Table 154. Shanghai Junshi Biosciences Co., Ltd. Competitive Strengths & Weaknesses
Table 155. Akeso, Inc. Basic Information, Manufacturing Base and Competitors
Table 156. Akeso, Inc. Major Business
Table 157. Akeso, Inc. Anticancer Biologics Product and Services
Table 158. Akeso, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Akeso, Inc. Recent Developments/Updates
Table 160. Akeso, Inc. Competitive Strengths & Weaknesses
Table 161. Shanghai Henlius Biotech, Inc. Basic Information, Manufacturing Base and Competitors
Table 162. Shanghai Henlius Biotech, Inc. Major Business
Table 163. Shanghai Henlius Biotech, Inc. Anticancer Biologics Product and Services
Table 164. Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Shanghai Henlius Biotech, Inc. Recent Developments/Updates
Table 166. Shanghai Henlius Biotech, Inc. Competitive Strengths & Weaknesses
Table 167. RemeGen Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 168. RemeGen Co., Ltd. Major Business
Table 169. RemeGen Co., Ltd. Anticancer Biologics Product and Services
Table 170. RemeGen Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. RemeGen Co., Ltd. Recent Developments/Updates
Table 172. RemeGen Co., Ltd. Competitive Strengths & Weaknesses
Table 173. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 174. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
Table 175. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product and Services
Table 176. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments/Updates
Table 178. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 179. Sino Biopharmaceutical Limited Basic Information, Manufacturing Base and Competitors
Table 180. Sino Biopharmaceutical Limited Major Business
Table 181. Sino Biopharmaceutical Limited Anticancer Biologics Product and Services
Table 182. Sino Biopharmaceutical Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Sino Biopharmaceutical Limited Recent Developments/Updates
Table 184. Sino Biopharmaceutical Limited Competitive Strengths & Weaknesses
Table 185. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 186. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Major Business
Table 187. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product and Services
Table 188. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Recent Developments/Updates
Table 190. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Competitive Strengths & Weaknesses
Table 191. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 192. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Major Business
Table 193. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product and Services
Table 194. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recent Developments/Updates
Table 196. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
Table 197. Global Key Players of Anticancer Biologics Upstream (Raw Materials)
Table 198. Global Anticancer Biologics Typical Customers
Table 1. World Anticancer Biologics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Anticancer Biologics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Anticancer Biologics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Anticancer Biologics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Anticancer Biologics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Anticancer Biologics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Anticancer Biologics Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Anticancer Biologics Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Anticancer Biologics Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Anticancer Biologics Players in 2025
Table 12. World Anticancer Biologics Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Anticancer Biologics Company Evaluation Quadrant
Table 14. Head Office of Key Anticancer Biologics Players
Table 15. Anticancer Biologics Market: Company Product Type Footprint
Table 16. Anticancer Biologics Market: Company Product Application Footprint
Table 17. Anticancer Biologics Mergers & Acquisitions Activity
Table 18. United States VS China Anticancer Biologics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Anticancer Biologics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Anticancer Biologics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Anticancer Biologics Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Anticancer Biologics Revenue Market Share (2021-2026)
Table 23. China Based Anticancer Biologics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Anticancer Biologics Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Anticancer Biologics Revenue Market Share (2021-2026)
Table 26. Rest of World Based Anticancer Biologics Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Anticancer Biologics Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Anticancer Biologics Revenue Market Share (2021-2026)
Table 29. World Anticancer Biologics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Anticancer Biologics Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Anticancer Biologics Market Size by Type (2027-2032) & (USD Million)
Table 32. World Anticancer Biologics Market Size by Target, (USD Million), 2021 & 2025 & 2032
Table 33. World Anticancer Biologics Market Size Value by Target (2021-2026) & (USD Million)
Table 34. World Anticancer Biologics Market Size by Target (2027-2032) & (USD Million)
Table 35. World Anticancer Biologics Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 36. World Anticancer Biologics Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 37. World Anticancer Biologics Market Size by Route of Administration (2027-2032) & (USD Million)
Table 38. World Anticancer Biologics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Anticancer Biologics Market Size by Application (2021-2026) & (USD Million)
Table 40. World Anticancer Biologics Market Size by Application (2027-2032) & (USD Million)
Table 41. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 42. AbbVie Inc. Major Business
Table 43. AbbVie Inc. Anticancer Biologics Product and Services
Table 44. AbbVie Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. AbbVie Inc. Recent Developments/Updates
Table 46. AbbVie Inc. Competitive Strengths & Weaknesses
Table 47. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 48. Johnson & Johnson Major Business
Table 49. Johnson & Johnson Anticancer Biologics Product and Services
Table 50. Johnson & Johnson Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Johnson & Johnson Recent Developments/Updates
Table 52. Johnson & Johnson Competitive Strengths & Weaknesses
Table 53. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 54. Novartis AG Major Business
Table 55. Novartis AG Anticancer Biologics Product and Services
Table 56. Novartis AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Novartis AG Recent Developments/Updates
Table 58. Novartis AG Competitive Strengths & Weaknesses
Table 59. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 60. Gilead Sciences, Inc. Major Business
Table 61. Gilead Sciences, Inc. Anticancer Biologics Product and Services
Table 62. Gilead Sciences, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Gilead Sciences, Inc. Recent Developments/Updates
Table 64. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 65. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 66. Roche Holding AG Major Business
Table 67. Roche Holding AG Anticancer Biologics Product and Services
Table 68. Roche Holding AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Roche Holding AG Recent Developments/Updates
Table 70. Roche Holding AG Competitive Strengths & Weaknesses
Table 71. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 72. Bristol-Myers Squibb Company Major Business
Table 73. Bristol-Myers Squibb Company Anticancer Biologics Product and Services
Table 74. Bristol-Myers Squibb Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Bristol-Myers Squibb Company Recent Developments/Updates
Table 76. Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
Table 77. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 78. Amgen Inc. Major Business
Table 79. Amgen Inc. Anticancer Biologics Product and Services
Table 80. Amgen Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Amgen Inc. Recent Developments/Updates
Table 82. Amgen Inc. Competitive Strengths & Weaknesses
Table 83. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 84. AstraZeneca plc Major Business
Table 85. AstraZeneca plc Anticancer Biologics Product and Services
Table 86. AstraZeneca plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. AstraZeneca plc Recent Developments/Updates
Table 88. AstraZeneca plc Competitive Strengths & Weaknesses
Table 89. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 90. Merck & Co., Inc. Major Business
Table 91. Merck & Co., Inc. Anticancer Biologics Product and Services
Table 92. Merck & Co., Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Merck & Co., Inc. Recent Developments/Updates
Table 94. Merck & Co., Inc. Competitive Strengths & Weaknesses
Table 95. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors
Table 96. Takeda Pharmaceutical Company Limited Major Business
Table 97. Takeda Pharmaceutical Company Limited Anticancer Biologics Product and Services
Table 98. Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 100. Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
Table 101. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 102. Merck KGaA Major Business
Table 103. Merck KGaA Anticancer Biologics Product and Services
Table 104. Merck KGaA Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Merck KGaA Recent Developments/Updates
Table 106. Merck KGaA Competitive Strengths & Weaknesses
Table 107. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 108. Eli Lilly and Company Major Business
Table 109. Eli Lilly and Company Anticancer Biologics Product and Services
Table 110. Eli Lilly and Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Eli Lilly and Company Recent Developments/Updates
Table 112. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 113. Ono Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 114. Ono Pharmaceutical Co., Ltd. Major Business
Table 115. Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product and Services
Table 116. Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Ono Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 118. Ono Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 119. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 120. Pfizer Inc. Major Business
Table 121. Pfizer Inc. Anticancer Biologics Product and Services
Table 122. Pfizer Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Pfizer Inc. Recent Developments/Updates
Table 124. Pfizer Inc. Competitive Strengths & Weaknesses
Table 125. GSK plc Basic Information, Manufacturing Base and Competitors
Table 126. GSK plc Major Business
Table 127. GSK plc Anticancer Biologics Product and Services
Table 128. GSK plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. GSK plc Recent Developments/Updates
Table 130. GSK plc Competitive Strengths & Weaknesses
Table 131. Regeneron Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 132. Regeneron Pharmaceuticals, Inc. Major Business
Table 133. Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product and Services
Table 134. Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 136. Regeneron Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 137. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors
Table 138. Innovent Biologics, Inc. Major Business
Table 139. Innovent Biologics, Inc. Anticancer Biologics Product and Services
Table 140. Innovent Biologics, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Innovent Biologics, Inc. Recent Developments/Updates
Table 142. Innovent Biologics, Inc. Competitive Strengths & Weaknesses
Table 143. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 144. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
Table 145. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product and Services
Table 146. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
Table 148. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
Table 149. Shanghai Junshi Biosciences Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 150. Shanghai Junshi Biosciences Co., Ltd. Major Business
Table 151. Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product and Services
Table 152. Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Shanghai Junshi Biosciences Co., Ltd. Recent Developments/Updates
Table 154. Shanghai Junshi Biosciences Co., Ltd. Competitive Strengths & Weaknesses
Table 155. Akeso, Inc. Basic Information, Manufacturing Base and Competitors
Table 156. Akeso, Inc. Major Business
Table 157. Akeso, Inc. Anticancer Biologics Product and Services
Table 158. Akeso, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Akeso, Inc. Recent Developments/Updates
Table 160. Akeso, Inc. Competitive Strengths & Weaknesses
Table 161. Shanghai Henlius Biotech, Inc. Basic Information, Manufacturing Base and Competitors
Table 162. Shanghai Henlius Biotech, Inc. Major Business
Table 163. Shanghai Henlius Biotech, Inc. Anticancer Biologics Product and Services
Table 164. Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Shanghai Henlius Biotech, Inc. Recent Developments/Updates
Table 166. Shanghai Henlius Biotech, Inc. Competitive Strengths & Weaknesses
Table 167. RemeGen Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 168. RemeGen Co., Ltd. Major Business
Table 169. RemeGen Co., Ltd. Anticancer Biologics Product and Services
Table 170. RemeGen Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. RemeGen Co., Ltd. Recent Developments/Updates
Table 172. RemeGen Co., Ltd. Competitive Strengths & Weaknesses
Table 173. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 174. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
Table 175. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product and Services
Table 176. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments/Updates
Table 178. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 179. Sino Biopharmaceutical Limited Basic Information, Manufacturing Base and Competitors
Table 180. Sino Biopharmaceutical Limited Major Business
Table 181. Sino Biopharmaceutical Limited Anticancer Biologics Product and Services
Table 182. Sino Biopharmaceutical Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Sino Biopharmaceutical Limited Recent Developments/Updates
Table 184. Sino Biopharmaceutical Limited Competitive Strengths & Weaknesses
Table 185. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 186. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Major Business
Table 187. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product and Services
Table 188. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Recent Developments/Updates
Table 190. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Competitive Strengths & Weaknesses
Table 191. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 192. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Major Business
Table 193. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product and Services
Table 194. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recent Developments/Updates
Table 196. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
Table 197. Global Key Players of Anticancer Biologics Upstream (Raw Materials)
Table 198. Global Anticancer Biologics Typical Customers
LIST OF FIGURES
Figure 1. Anticancer Biologics Picture
Figure 2. World Anticancer Biologics Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Anticancer Biologics Total Revenue (2021-2032) & (USD Million)
Figure 4. World Anticancer Biologics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Anticancer Biologics Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 13. Anticancer Biologics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 16. World Anticancer Biologics Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 18. China Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 23. India Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Anticancer Biologics by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Anticancer Biologics Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Anticancer Biologics Markets in 2025
Figure 27. United States VS China: Anticancer Biologics Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Anticancer Biologics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Anticancer Biologics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Anticancer Biologics Market Size Market Share by Type in 2025
Figure 31. Antibody Therapies
Figure 32. Antibody-Drug Conjugates (ADCs)
Figure 33. Cell Therapies
Figure 34. Cancer Vaccines and Oncolytic Viruses
Figure 35. Others
Figure 36. World Anticancer Biologics Market Size Market Share by Type (2021-2032)
Figure 37. World Anticancer Biologics Market Size by Target, (USD Million), 2021 & 2025 & 2032
Figure 38. World Anticancer Biologics Market Size Market Share by Target in 2025
Figure 39. Immune Checkpoint Targets
Figure 40. Solid Tumor-Associated Targets
Figure 41. Hematologic Tumor Targets
Figure 42. Angiogenesis-Related Targets
Figure 43. Others
Figure 44. World Anticancer Biologics Market Size Market Share by Target (2021-2032)
Figure 45. World Anticancer Biologics Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 46. World Anticancer Biologics Market Size Market Share by Route of Administration in 2025
Figure 47. Intravenous Administration
Figure 48. Subcutaneous Administration
Figure 49. Cell Infusion
Figure 50. Intratumoral Administration
Figure 51. Others
Figure 52. World Anticancer Biologics Market Size Market Share by Route of Administration (2021-2032)
Figure 53. World Anticancer Biologics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 54. World Anticancer Biologics Market Size Market Share by Application in 2025
Figure 55. Lung Cancer
Figure 56. Breast Cancer
Figure 57. Hematologic Cancers
Figure 58. Gastrointestinal Cancers
Figure 59. Others
Figure 60. World Anticancer Biologics Market Size Market Share by Application (2021-2032)
Figure 61. Anticancer Biologics Industrial Chain
Figure 62. Methodology
Figure 63. Research Process and Data Source
Figure 1. Anticancer Biologics Picture
Figure 2. World Anticancer Biologics Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Anticancer Biologics Total Revenue (2021-2032) & (USD Million)
Figure 4. World Anticancer Biologics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Anticancer Biologics Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Anticancer Biologics Revenue (2021-2032) & (USD Million)
Figure 13. Anticancer Biologics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 16. World Anticancer Biologics Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 18. China Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 23. India Anticancer Biologics Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Anticancer Biologics by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Anticancer Biologics Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Anticancer Biologics Markets in 2025
Figure 27. United States VS China: Anticancer Biologics Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Anticancer Biologics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Anticancer Biologics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Anticancer Biologics Market Size Market Share by Type in 2025
Figure 31. Antibody Therapies
Figure 32. Antibody-Drug Conjugates (ADCs)
Figure 33. Cell Therapies
Figure 34. Cancer Vaccines and Oncolytic Viruses
Figure 35. Others
Figure 36. World Anticancer Biologics Market Size Market Share by Type (2021-2032)
Figure 37. World Anticancer Biologics Market Size by Target, (USD Million), 2021 & 2025 & 2032
Figure 38. World Anticancer Biologics Market Size Market Share by Target in 2025
Figure 39. Immune Checkpoint Targets
Figure 40. Solid Tumor-Associated Targets
Figure 41. Hematologic Tumor Targets
Figure 42. Angiogenesis-Related Targets
Figure 43. Others
Figure 44. World Anticancer Biologics Market Size Market Share by Target (2021-2032)
Figure 45. World Anticancer Biologics Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 46. World Anticancer Biologics Market Size Market Share by Route of Administration in 2025
Figure 47. Intravenous Administration
Figure 48. Subcutaneous Administration
Figure 49. Cell Infusion
Figure 50. Intratumoral Administration
Figure 51. Others
Figure 52. World Anticancer Biologics Market Size Market Share by Route of Administration (2021-2032)
Figure 53. World Anticancer Biologics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 54. World Anticancer Biologics Market Size Market Share by Application in 2025
Figure 55. Lung Cancer
Figure 56. Breast Cancer
Figure 57. Hematologic Cancers
Figure 58. Gastrointestinal Cancers
Figure 59. Others
Figure 60. World Anticancer Biologics Market Size Market Share by Application (2021-2032)
Figure 61. Anticancer Biologics Industrial Chain
Figure 62. Methodology
Figure 63. Research Process and Data Source
